Recombinant Human Intercellular adhesion molecule 3 (ICAM3)

What is the basic structure of human ICAM3?

Human ICAM3 (also known as CD50) is a type I transmembrane glycoprotein with a total gene length of 1644 base pairs, encoding 547 amino acids. Its structure consists of three distinct domains: an extracellular region containing five type C2 immunoglobulin-like repeats (484 amino acids), a transmembrane segment (30 amino acids), and an intracellular C-terminal domain (34 amino acids). The human ICAM3 gene is located in chromosome region 19p13.2-p13.3, positioned close to the ICAM1 gene. Sequence analysis reveals that ICAM3 shares 51% structural similarity with ICAM1 and 37% similarity with ICAM2, suggesting potential functional overlap while maintaining distinct biological roles .

How does ICAM3 differ structurally from other ICAM family members?

While ICAM3 shares the core immunoglobulin-like domain structure with other ICAM family members, it has distinctive features. Compared to ICAM1 and ICAM2, ICAM3 possesses unique glycosylation patterns, particularly the presence of Lewis x residues that facilitate specific interactions with dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN). This glycosylation signature distinguishes ICAM3 from other family members and contributes to its specialized functions in immune cell interactions. Additionally, ICAM3 has not been identified in mice, making it a human-specific adhesion molecule, which has implications for experimental design in research settings .

What are the known binding partners of ICAM3?

ICAM3 interacts with multiple binding partners in the immune system. The primary receptors include:

• Leukocyte Function-Associated Antigen-1 (LFA-1, also known as CD11a/CD18): This integrin is the main binding partner on T lymphocytes.

• Alpha d/beta 2 integrin: Another leukocyte integrin that interacts with ICAM3.

• DC-SIGN (Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin): This C-type lectin on macrophages and dendritic cells recognizes Lewis x residues on ICAM3.

These interactions mediate critical cellular processes including leukocyte adhesion, dendritic cell-T cell contact formation, and signal transduction pathways that regulate immune cell activation and function .

What is the expression pattern of ICAM3 in normal human tissues?

ICAM3 is predominantly expressed on leukocytes and epidermal Langerhans cells. Within the leukocyte population, ICAM3 is constitutively expressed at high levels on resting lymphocytes, making it distinct from ICAM1 which is upregulated upon activation. Flow cytometry analysis has demonstrated that resting blood dendritic cells (DCs) express significantly more ICAM3 than ICAM1 or ICAM2. This expression pattern suggests that ICAM3 plays a crucial role in the initial phases of immune cell interactions, particularly in the context of T cell activation by antigen-presenting cells .

How is ICAM3 expression regulated in response to inflammatory stimuli?

ICAM3 expression demonstrates distinct regulatory patterns compared to other adhesion molecules. While ICAM1 expression on dendritic cells is significantly upregulated in response to interferon-gamma treatment, ICAM3 levels remain relatively constant under the same conditions. This differential regulation suggests that ICAM3 serves constitutive functions in immune cell interactions, whereas ICAM1 may play a more dynamic role in inflammation. The stability of ICAM3 expression makes it a reliable surface marker for identifying and isolating specific leukocyte populations across different inflammatory states .

What are the transcript variants of ICAM3 and their functional differences?

ICAM3 exists in multiple transcript variants with distinct structural features and functions:

• Variant 1 (1644 bp, 547 amino acids, 60 kDa): The longest variant

• Variant 2 (1356 bp, 451 amino acids, 49 kDa): Contains a 288 bp deletion in the middle portion

• Variant 3 (1413 bp, 470 amino acids, 51 kDa): Contains a 231 bp deletion at the beginning

• Variant 4 (861 bp, 286 amino acids, 31 kDa): Contains a 783 bp deletion at the beginning

Expression analysis in diffuse large B-cell lymphoma (DLBCL) revealed that variants 1, 3, and 4 are expressed in normal B-cell lines and most DLBCL cell lines, while variant 2 expression is not detected. Functional studies indicate that variants 1, 3, and 4 promote cell cycle progression, proliferation, migration, and epithelial-mesenchymal transition in DLBCL cells, whereas variant 2 lacks these effects. These findings highlight the importance of characterizing specific variants when studying ICAM3 function in different cellular contexts .

What are the best methods for producing recombinant human ICAM3?

Production of high-quality recombinant human ICAM3 for research applications typically involves:

• Expression System Selection: Mammalian expression systems (HEK293 or CHO cells) are preferred over bacterial systems to ensure proper glycosylation, particularly the Lewis x residues critical for DC-SIGN binding.

• Vector Design: Using expression vectors containing the full-length ICAM3 cDNA (1644 bp) with appropriate epitope or affinity tags (His, Fc, etc.) for purification. For specific applications, researchers may choose to express particular domains or variants.

• Purification Strategy:

  • Initial capture using affinity chromatography (Ni-NTA for His-tagged proteins or Protein A/G for Fc-fusion proteins)

  • Polishing steps using ion exchange and size exclusion chromatography

  • Quality control via SDS-PAGE, Western blotting, and glycosylation analysis

• Functional Validation: Testing binding to known partners like LFA-1 and DC-SIGN using surface plasmon resonance or cell-based binding assays.

The resulting recombinant ICAM3 should be stored with glycerol or stabilizing agents at -70°C with minimal freeze-thaw cycles to preserve functionality .

How can researchers effectively detect and quantify ICAM3 expression in different cell types?

Multiple complementary approaches can be employed to detect and quantify ICAM3 expression:

• Flow Cytometry: Using monoclonal antibodies specific to ICAM3 (such as Cal 3.10 clone) for cell surface expression analysis. This method allows for quantitative assessment of ICAM3 levels on individual cells within heterogeneous populations.

• Immunohistochemistry/Immunofluorescence: For tissue localization studies, using formalin-fixed paraffin-embedded or frozen sections.

• Western Blotting: For total protein expression analysis, particularly useful for distinguishing between different ICAM3 transcript variants based on molecular weight.

• qRT-PCR: For transcript-specific expression analysis, using primers designed to distinguish between the four known ICAM3 variants.

• ELISA: For quantification of soluble ICAM3 in biological fluids.

When comparing ICAM3 expression across different conditions or cell types, it is crucial to include appropriate controls and normalize expression to stable reference markers .

What are the recommended approaches for studying ICAM3-mediated cell-cell interactions?

Several methodological approaches can be employed to study ICAM3-mediated cellular interactions:

• Static Adhesion Assays: Coating surfaces with recombinant ICAM3-Fc chimeric proteins and quantifying adherent cells expressing LFA-1 or other binding partners.

• Flow-Based Adhesion Assays: Using microfluidic devices to study adhesion under physiological shear stress conditions.

• Co-Immunoprecipitation: To identify molecular complexes involving ICAM3 and its binding partners in different cell types.

• Functional Blocking Studies: Using monoclonal antibodies like CAL 3.10 to selectively inhibit ICAM3 interactions in mixed leukocyte reactions or other functional assays. Studies have shown that anti-ICAM-3 antibodies inhibit dendritic cell-stimulated mixed leukocyte reactions to a greater extent than anti-ICAM-1 or anti-ICAM-2 reagents.

• Live Cell Imaging: Fluorescently labeled cells to visualize dynamic interactions between ICAM3-expressing cells and their binding partners.

• CRISPR/Cas9 Gene Editing: For creating ICAM3 knockout or variant-specific cell lines to study function in relevant cellular contexts .

What is the specific role of ICAM3 in dendritic cell-T cell interactions?

ICAM3 plays a crucial role in the initial contact formation between dendritic cells (DCs) and T lymphocytes during antigen presentation:

• Initial Cell Contact: As the predominant LFA-1 ligand on resting blood DCs, ICAM3 mediates the early physical interactions with T cells. Flow cytometry studies have shown that resting blood DCs express significantly more ICAM3 than ICAM1 or ICAM2.

• Co-stimulatory Function: Solid-phase recombinant ICAM3-Fc chimeric molecules can co-stimulate CD4+ T lymphocyte proliferation when combined with suboptimal CD3 antibody stimulation. This suggests ICAM3 provides essential secondary signals for T cell activation.

• Temporal Regulation: While ICAM3 is crucial for initial DC-T cell contact, ICAM1 (which is upregulated upon DC activation) likely contributes to later phases of T cell activation and sustained interactions.

• Functional Evidence: Blocking studies with the anti-ICAM3 monoclonal antibody CAL 3.10 significantly inhibit DC-stimulated mixed leukocyte reactions, more effectively than anti-ICAM1 or anti-ICAM2 antibodies. This demonstrates the non-redundant role of ICAM3 in immune synapse formation and function .

How does the glycosylation pattern of ICAM3 influence its immune functions?

The glycosylation pattern of ICAM3, particularly the presence of Lewis x residues, is critical for its specialized immune functions:

• DC-SIGN Recognition: Native ICAM3 from human peripheral leukocytes contains Lewis x structures that are specifically recognized by DC-SIGN on dendritic cells. This interaction is distinct from the ICAM3-LFA-1 binding and represents an alternative pathway for immune cell communication.

• Cell-Type Specificity: Interestingly, only ICAM3 from granulocytes within peripheral blood cell populations binds effectively to DC-SIGN. This suggests that cell type-specific glycosylation patterns create functional diversity in ICAM3-mediated interactions.

• Fucosyltransferase Regulation: The synthesis of Lewis x residues on ICAM3 is primarily mediated by fucosyltransferase IX (FUT IX) and to a lesser extent by FUT IV, but not by FUT III or VII. This enzymatic regulation provides a potential mechanism for controlling ICAM3 functionality through modulation of its glycosylation.

• Functional Consequences: The Lewis x-mediated binding of ICAM3 to DC-SIGN likely facilitates interactions between granulocytes and dendritic cells, potentially influencing antigen transfer, inflammatory responses, and immune surveillance .

What is the role of ICAM3 in cancer progression and metastasis?

ICAM3 demonstrates complex and sometimes contradictory roles in cancer biology:

• Expression Patterns: ICAM3 expression varies significantly across cancer types. Analysis using databases like GEPIA, TIMER, UALCAN, and TNMplot has revealed inconsistent expression patterns even within the same cancer type. For example, in acute granulocytic leukemia, GEPIA showed high expression of ICAM3 relative to normal tissue, while TNMplot indicated low expression.

• Cancer Stemness Regulation: Knockdown studies have shown that reduced ICAM3 expression significantly inhibits OCT4 promoter activity and decreases the proportion of ALDH+ cancer stem cells. Mechanistically, ICAM3 activates Src through its intracellular YLPL sequence, which in turn activates the PI3K/AKT signaling pathway, enhancing the activity of stemness factors like OCT4.

• Inflammatory Signaling Loop: ICAM3 promotes NF-κB nuclear translocation through the Src/PI3K/AKT pathway. NF-κB then binds to the ICAM3 promoter, creating a positive feedback loop that enhances ICAM3 expression and inflammatory cytokine secretion.

• Therapeutic Implications: Small-molecule inhibitors targeting ICAM3 signaling molecules (Src, PI3K) can inhibit ICAM3 expression, inflammation, and cancer stem cell properties, suggesting potential therapeutic approaches .

How is ICAM3 implicated in neurological disorders?

Recent research has identified ICAM3 as a potential factor in several neurological conditions:

• Epilepsy: Brain transcriptome-wide and protein-wide association studies with chemical-gene interaction analysis identified ICAM3 as one of five important genes related to epilepsy (along with WIPF1, IQSEC1, JAM2, and ZNF143). This suggests ICAM3 may represent a novel target for drug development in epilepsy treatment.

• Intracranial Aneurysms (IA): Quantitative proteomics approaches analyzing tissues from animal models and sera from human patients have identified ICAM3 as part of a seven-protein diagnostic classifier (ADAM12, APOL3, F9, C3, CEACAM1, ICAM3, KLHDC7A) that can differentiate ruptured from unruptured intracranial aneurysms with 95% accuracy. This suggests a potential role for ICAM3 as a biomarker for risk stratification in aneurysm patients.

• Acute Ischemic Stroke: Studies have suggested that circulating ICAM3 may serve as a potential short-term prognostic biomarker for acute ischemic stroke, helping to identify patients at higher risk for poor outcomes .

What are the contradictions in ICAM3 expression data across different cancer databases?

Researchers studying ICAM3 in cancer face significant challenges due to contradictory expression data across different databases:

• Database Discrepancies: Analysis of ICAM3 expression across 31 cancer types using GEPIA, TIMER, UALCAN, and TNMplot databases reveals inconsistent patterns. For example:

  • In acute granulocytic leukemia: GEPIA shows high expression while TNMplot shows low expression

  • In renal cancer: GEPIA and TIMER show high expression while TNMplot and UALCAN show low expression

• Potential Explanations: Several factors may contribute to these discrepancies:

  • Sample source heterogeneity (different regions or ethnic backgrounds)

  • Varying sample sizes for normal and cancer tissues

  • Different detection methodologies and data processing algorithms

  • Potential transcript variant-specific expression differences not captured by all platforms

• Research Implications: These contradictions highlight the importance of:

  • Validating expression findings in independent cohorts

  • Using multiple detection methods (qPCR, Western blot, IHC)

  • Considering transcript variant-specific analysis

  • Interpreting database findings cautiously and in the context of functional validation .

How can ICAM3 variants be leveraged for targeted therapeutic development?

Understanding the structural and functional diversity of ICAM3 variants opens several avenues for therapeutic development:

• Variant-Specific Targeting: The four ICAM3 transcript variants (1, 2, 3, and 4) show different functional properties in cancer cells. Variant-specific antibodies or small molecule inhibitors could selectively target disease-promoting variants while sparing those with normal physiological functions.

• Signaling Pathway Intervention: ICAM3 activates the Src/PI3K/AKT pathway and promotes NF-κB nuclear translocation. Inhibitors targeting these downstream effectors have shown promise in blocking ICAM3-mediated cancer stemness and inflammatory responses. Combination approaches targeting multiple nodes in this pathway might enhance therapeutic efficacy.

• Glycoengineering Approaches: Since the Lewis x glycosylation pattern is crucial for ICAM3-DC-SIGN interactions, modulating fucosyltransferases (particularly FUT IX) could alter immune cell communication in a targeted manner.

• Recombinant ICAM3 Domains: Engineered soluble ICAM3 domains could serve as decoys to block pathological interactions while preserving essential functions .

What are the methodological challenges in studying ICAM3-dependent signaling pathways?

Researchers investigating ICAM3 signaling face several methodological challenges:

• Pathway Complexity: ICAM3 activates multiple overlapping signaling pathways (Src, PI3K/AKT, NF-κB) that interact with other cellular signaling networks. Distinguishing ICAM3-specific effects requires careful experimental design with appropriate controls and pathway inhibitors.

• Cell Type Specificity: ICAM3 functions differently across cell types due to variations in binding partner expression and downstream signaling machinery. Studies must account for this heterogeneity when extrapolating findings between systems.

• Variant-Specific Effects: The four ICAM3 transcript variants have different signaling properties. Researchers must ensure their experimental systems account for variant expression and perform variant-specific knockdown or overexpression to delineate individual contributions.

• Temporal Dynamics: ICAM3 signaling exhibits temporal regulation, with some effects occurring rapidly after engagement and others requiring sustained interaction. Time-course experiments with appropriate resolution are essential.

• Technical Approaches:

  • Phosphoproteomic analysis to capture fast signaling events

  • ChIP-seq for NF-κB binding studies

  • Live-cell imaging with fluorescent reporters for dynamic pathway activation

  • Single-cell approaches to address heterogeneity in responses .

What are the emerging roles of ICAM3 in disease biomarker development?

Recent research highlights ICAM3's potential as a biomarker across multiple disease contexts:

• Cancer Prognosis: Studies correlating ICAM3 expression with patient survival across various cancer types suggest its utility as a prognostic biomarker. GEPIA and UALCAN database analyses reveal significant associations between ICAM3 expression and survival outcomes in several cancers, though these associations are not consistent across all cancer types.

• Neurological Disorders:

  • In acute ischemic stroke, circulating ICAM3 levels may serve as a short-term prognostic biomarker

  • In intracranial aneurysms, ICAM3 forms part of a seven-protein classifier with 95% accuracy for differentiating ruptured from unruptured aneurysms

• Multi-marker Panels: ICAM3 shows greatest promise when incorporated into multi-marker panels rather than as a standalone biomarker. For example, combining ICAM3 with other proteins like ADAM12, APOL3, F9, C3, CEACAM1, and KLHDC7A significantly improves diagnostic accuracy for intracranial aneurysms.

• Methodological Considerations:

  • Detection in biological fluids requires sensitive techniques like mass spectrometry or high-sensitivity ELISA

  • Variant-specific detection may offer improved specificity for particular disease states

  • Longitudinal sampling may be necessary to capture dynamic changes in ICAM3 levels during disease progression .